Assyro AI

Orange Book product · Brand (NDA)

WEGOVY

SEMAGLUTIDE

Brand (NDA)NDA 218316RX NOVO

At a glance

Dec 22, 2025

Approved

Brand (NDA)

Application

Not listed

TE code

8

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Dec 22, 2025

    6 mo ago

  2. Patent 8536122 expires

    Listed drug substance patent expiration.

    Mar 20, 2026

    3 mo ago

  3. Today

  4. Exclusivity ends · I-935

    New indication exclusivity (3 years)

    Mar 08, 2027

    in 9 mo

  5. Exclusivity ends · NP

    New product exclusivity (3 years)

    Dec 22, 2028

    in 2 yr 7 mo

  6. Patent 8129343 expires

    Listed drug substance patent expiration.

    Dec 05, 2031

    in 5 yr 7 mo

  7. Patent 11382957 expires

    Listed drug product patent expiration.

    Dec 16, 2031

    in 5 yr 7 mo

  8. Patent 11033499 expires

    Listed drug product patent expiration.

    Jun 19, 2033

    in 7 yr 1 mo

  9. Patent 10278923 expires

    Listed method-of-use patent (U-4389) expiration.

    May 02, 2034

    in 8 yr

  10. Patent 12239739 expires

    Listed method-of-use patent (U-4388) expiration.

    May 02, 2034

    in 8 yr

  11. Patent 11833248 expires

    Listed drug product patent expiration.

    Feb 01, 2039

    in 12 yr 10 mo

  12. Patent 12396953 expires

    Listed drug product patent expiration.

    Feb 01, 2039

    in 12 yr 10 mo

Pharmaceutical detail

Active ingredient

SEMAGLUTIDE

Strength

1.5MG

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 218316

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

  • I-935New indication exclusivity (3 years)

    Mar 08, 2027

    in 9 mo

  • NPNew product exclusivity (3 years)

    Dec 22, 2028

    in 2 yr 7 mo

Listed patents (8)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8536122Mar 20, 20263 mo ago
SubstanceProduct
8129343Dec 05, 2031in 5 yr 7 mo
SubstanceProduct
11382957Dec 16, 2031in 5 yr 7 mo
Product
11033499Jun 19, 2033in 7 yr 1 mo
ProductU-4496
10278923May 02, 2034in 8 yr
U-4389
12239739May 02, 2034in 8 yr
U-4388
11833248Feb 01, 2039in 12 yr 10 mo
ProductU-4387
12396953Feb 01, 2039in 12 yr 10 mo
ProductU-4387
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.